Launch week offerEnds in00h00m00s

annual Promonthly Pro

Debabrata Roy

Head of Epidemiology and Research

Drug Safety Research Unit

United Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United Kingdom

About

Debabrata Roy is the Head of Epidemiology and Research at the Drug Safety Research Unit in the United Kingdom. His research areas focus on pharmacovigilance, particularly the safety and effectiveness of medications and vaccines, as well as reproductive health. Recent publications include investigations into the safety of COVID-19 vaccines, long-term effects of contraceptives, and the pharmacological management of various health conditions.

Articles (13)

Year:

2026

Year:

2025

Year:

2025

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (4)

Samantha Martin

Head of Research

Drug Safety Research Unit

UNITED KINGDOM

View details

Hazel Clothier

University of Melbourne

AUSTRALIA

View details

Carlo Alberto Bissacco

Institut de Recerca en Atenció Primària Jordi Gol

SPAIN

View details

Felipe Villalobos Martínez

Institut de Recerca en Atenció Primària Jordi Gol

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Debabrata Roy

Research Interests

Make your next move.

Explore related searches

About

Articles (13)

Validation of Guillain-Barre syndrome case identification in three heterogeneous VAC4EU real-world data sources in Spain using the Brighton Collaboration criteria

Safety and effectiveness of the anti‐amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective

Safety and utilisation of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine: a UK post-authorisation active surveillance study

Delayed pregnancy detection and return to fertility with extended levonorgestrel-containing oral contraceptives: A real world setting cohort study.

Long-term safety of extended levonorgestrel-containing oral contraceptives in the United States

A Systematic Review of Flurbiprofen 8.75 mg Dose and Risk of Haemorrhagic Events.

Utilisation and Safety of Polyethylene Glycol 3350 With Electrolytes in Children Under 2 Years: A Retrospective Cohort.

Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study.

Real world utilization of 91 day extended levonorgestrel-containing combined oral contraceptives in Europe: a multinational database study.

Evaluation of the incidence of bleeding in patients prescribed rivaroxaban for the treatment and prevention of deep vein thrombosis and pulmonary embolism in UK secondary care: an observational cohort study.

Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study.

Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment.

Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment.

Collaborators (4)

Samantha Martin

Hazel Clothier

Carlo Alberto Bissacco

Felipe Villalobos Martínez

Make your next move.